Institute of Cancer Research, Medical University of Vienna, Austria.
PI: Maria Sibilia
Project: The oncogenic function of the EGFR is not only attributed to its expression in tumor cells, as we recently demonstrated that EGFR is upregulated in tumor-associated macrophages (TAMs) and myeloid cells, where it seems to promote tumor development. It is presently unclear how EGFR expression in TAMs affects their metabolic behavior.
Objectives: We aim to investigate the metabolic signatures of EGFR deficient and proficient myeloid cells, focusing first on myeloid cells isolated from mouse CRCs and validate these findings in human CRC.
Expected Results: We expect to gain information on the metabolic signatures of EGFR proficient and deficient myeloid cells isolated from CRC and how they affect cancer growth.
As part of our MSCA-ESR training on complementary skills we got to leave the wet lab to explore what happens on the other side of the bench and to learn what it means to be a scientific editor. This is our story.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 766214.
Bellvitge Biomedical
Research Institute (IDIBELL)
Hospital Duran i Reynals, 3a planta
Gran Via de l’Hospitalet, 199
08908 L’Hospitalet del Llobregat
Barcelona, Spain
